News | Press releases & other news
PRESS RELEASES
OTHER NEWS
Aug 16, 2024
View Lytix Biopharma's presentation of Phase II clinical results in Basal Cell Carcinoma
Nov 27, 2023
Øystein Rekdal, CEO in Lytix Biopharma, presented at Redeye Life Science Day 2023 in Stockholm – 23rd of November
Aug 14, 2023
The positive interim Phase II data with LTX-315 from Verrica Pharmaceuticals Inc. (Lytix Biopharma’s licensing partner) stirs attention
May 30, 2023
Lytix Biopharma’s innovative and unique solution emphasized in national clinical research report
May 12, 2023
Hear our CEO, Øystein Rekdal, explaining how our technology has the potential to solve the major challenge in current cancer therapy
May 8, 2023
"Norwegian cancer medicine is attracting attention", read article in TV2 news
Apr 12, 2023
First patient dosed in Part 2 of Verrica Pharmaceuticals' Phase II study evaluating LTX-315
Mar 22, 2023
Lytix Biopharma appoints Karsten Bruins Slot as Director Clinical Development
Mar 7, 2023
Verrica Pharmaceuticals with positive update on how they are advancing our lead compound LTX-315 through their Phase II trial
Nov 23, 2022
Lytix Biopharma held a CMD November 22nd, 2022 - webcast replay is available
Jun 20, 2022
Lytix Biopharma to present at the 5th Annual Next-Gen Immuno-Oncology Conference in Boston, USA
Jun 5, 2022
Lytix Biopharma with new data at ASCO - featured in Finansavisen and in Dagens Medisin
Dec 17, 2021
Øystein Rekdal, CEO in Lytix Biopharma, interviewed live at 'Økonomi-nyheter', Finansavisen
Nov 22, 2021
Lytix Biopharma will release its third quarter 2021 results on Thursday, 25 November
Nov 18, 2021
FDA has accepted Verrica's IND for LTX-315 in treatment of basal cell carcinoma
Nov 12, 2021
Lytix presents encouraging preclinical data in triple negative breast cancer in collaboration with Weill Cornell Medicine
Nov 2, 2021
On this day in 1982 Nobel Prize laureate, and our SAB member, James Allison published a paper in the Journal of Immunology identifying the protein structure of the T-cell receptor, the previously mysterious ignition switch for immune response
Oct 22, 2021
Lytix Biopharma granted European Patent for LTX-315 in combination with chemotherapeutic agent
Oct 18, 2021
Øystein Rekdal presents Lytix Biopharma at Finansavisen’s ‘INVESTORDAGENE 2021’
Sep 23, 2021
Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US
Aug 27, 2021
Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market
Aug 23, 2021
Lytix Biopharma presents first half and second quarter 2021 results, Friday 27 August
Jul 15, 2021
Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors
May 31, 2021
Lytix Biopharma AS: Contemplated private placement and listing on Euronext Growth Oslo
May 25, 2021
Lytix Biopharma strengthens the board of directors with nominating Marie-Louise Fjällskog, Evelina Vågesjö, Kjetil Hestdal and Jayson Rieger as new directors
Mar 29, 2021
Lytix Biopharma enters into an exclusive license agreement with the Arctic University of Norway for a class of new drug candidates - and forms a strategic partnership with the US-based Aurelius Biotherapeutics
Feb 27, 2021
CEO in Lytix Biopharma gives oral presentation at ESMO targeted anticancer therapies virtual congress 2021
Feb 26, 2021
Lytix Biopharma is delighted to share our latest publication in “Trends in Cancer”
Jan 20, 2021
Lytix Biopharma announces FDA clearance of IND for starting a Phase II study in the US
Aug 12, 2020
Lytix Biopharma enters milestone agreement with Verrica Pharmaceuticals for its lead candidate LTX-315
May 25, 2020
CSO in Lytix Biopharma participates in panel debate arranged by OCC, LMI and NCS
Jan 15, 2020
Lytix Biopharma among 11 finalists at the third annual Lyfebulb-Helsinn Innovation Summit
Dec 23, 2019
James P. Allison, SAB member in Lytix Biopharma, featured in VG today - and Lytix is mentioned
Dec 11, 2019
Today Lytix Biopharma's CEO gave his presentation ‘Addressing heterogeneity: A hot topic’ at ESMO
Nov 11, 2019
Lytix Biopharma is featured in Finansavisen, talking about Iovance collaboration and funding
Nov 10, 2019
Lytix Biopharma announces a clinical collaboration agreement with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Oct 23, 2019
New publication in collaboration with Mikael Pittet and his team at Massachusetts General Hospital and Harvard Medical School
Jun 20, 2019
Lytix Biopharma announces two recent publications on LTX-401, a second generation molecule developed for treatment of visceral tumors
Jun 20, 2019
Intratumoral treatment with LTX-315 causes regression of Desmoid Tumor- A case history
Jun 13, 2019
Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma joins Lytix as Company Strategic Advisors and in SAB
May 14, 2019
Lytix Biopharma is invited as a speaker at a Medicon Valley Alliance meeting
Nov 27, 2018
Lytix Biopharma presented at the Investival showcase at the Jefferies Healthcare Conference in London
Nov 21, 2018
Lytix Biopharma announces positive top-line data from a Phase 1 study with LTX-315
Jun 12, 2018
Lytix Biopharma strengthens management with appointment of Hamina Patel as CMO
May 25, 2018
Lytix Biopharma will present preliminary data at ASCO from a phase I/II study
Apr 11, 2018
Lytix Biopharma invited to China together with the Norwegian Minister of Health and Care Services
Jan 30, 2018
Recruitment of patients in the breast cancer arm was strong and is completed
Dec 20, 2017
Lytix Biopharma receives funding for innovation partnership with OncoImmunity in search for neoantigens
Sep 20, 2017
Lytix among the speakers at Redeye’s ‘Fight cancer – immune-oncology’ conference
Aug 31, 2017
LTX-315’s ability to induce abscopal anticancer activity published in OncoImmunology
Aug 21, 2017
Lytix strengthens the board with clinical development and commercial oncology experience
Jun 6, 2017
HalioDx SAS, an immuno-oncology diagnostic company, was co-authors at the poster of Phase I data on LTX-315 at ASCO
May 21, 2017
Immunotherapeutic effects of LTX-315 published in Future Medicinal Chemistry
Apr 21, 2017
Lytix Biopharma completes 1st combination cohort of LTX-315 and pembrolizumab in TNBC
Apr 3, 2017
LTX-315 was presented at ICI Boston (a dedicated Cancer Immunotherapy meeting) in March 2017
Mar 8, 2017
Lytix Biopharma presented at the 10th Annual European Life Sciences CEO Forum & Exhibition
Jan 6, 2017
Lytix Biopharma present at J.P. Morgan 35th Annual Healthcare Conference 2017, in San Francisco
Nov 11, 2016
Håkan Wickholm presents Lytix Biopharma at Redeye Life Science Seminar 2016
Sep 21, 2016
Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors
Sep 21, 2016
Håkan Wickholm presents Lytix Biopharma at Sachs Annual Biotech in Europe Forum
Sep 15, 2016
Lytix Biopharma present at Nordic Life Science Days in Stockholm Sept 2016
Sep 1, 2016
Dr. Pittet at Massachusetts General Hospital and Harvard performs studies with LTX-315
May 11, 2016
At CIMT 2016 Lytix presented LTX-315's ability to make tumors more T-cell inflamed
Apr 27, 2016
Lytix Biopharma will do a presentation at BioEquity Europe in Copenhagen in May
Mar 30, 2016
The story behind the discovery of LTX-315 published in Journal of Medicinal Chemistry
Mar 21, 2016
A positive editorial discussion on LTX-315`s mode of action in the journal Cell Cycle
Feb 28, 2016
Lytix Biopharma is among promising cancer biotech companies featured in Norwegian article
Jan 21, 2016
In a difficult marked, Lytix had a successful share issue - read article in DN
Nov 23, 2015
Issuing of new shares in Lytix Biopharma, the subscription deadline is December 10, 2015
Oct 31, 2015
Lytix Biopharma shelves clinical trial with LTX-109 in diabetic foot ulcers
Sep 28, 2015
TV lecture on antibacterial compounds by one of Lytix Biopharma's founders
Sep 26, 2015
Lytix Biopharma presented initial results from LTX-315 Phase I study at ECC2015
Sep 9, 2015
Lytix Biopharma in panel discussion at Nordic Life Science Days in Stockholm Sept 9th 2015
Sep 9, 2015
Political seminar on knowledge-based reorganization to new growth and value creation
May 13, 2015
Lytix Biopharma invited to speak at Scandinavian Sarcoma group meeting in Stockholm
Apr 23, 2015
Lytix Biopharma presented at Anglonordic Life Science Conference XII in London
Dec 2, 2014
Listing of new shares in Lytix Biopharma, the subscription deadline is December 17, 2014
Nov 21, 2014
Lytix Biopharma appoints Andrew Saunders, M.D., FFPM as Chief Medical Officer
Oct 29, 2014
New article about LTX-109 published in ‘Antimicrobial Agents and Chemotherapy’
Oct 9, 2014
In his speach Oct 8th Minister Røe Isaksen put Lytix Biopharma forward as a good example
Sep 24, 2014
Lytix Biopharma got honored guests - NoMA Tuesday and two ministers Wednesday
Sep 5, 2014
LTX-315`s ability to cure B61 melanomas is published in two international journals
Aug 18, 2014
Lytix Biopharma attends Nordic Life Science Days in Stockholm September 7-9, 2014
Jun 10, 2014
Lytix Biopharma starts subsidiary within antimicrobial coating - Lytix Amicoat
Jun 6, 2014
Dr. Line presents LTX-315 data at International Liver Transplantation Society congress in London
Jun 1, 2014
June 1st Lytix Bioharma presented data at ASCO from the first LTX-315 clinical trial
May 28, 2014
Lytix Biopharma extends the research collaboration with Institute Gustave Roussy
May 6, 2014
Lytix Biopharma enters into partnership dialogue about further development of LTX-109
Apr 30, 2014
Lytix Biopharma is attending Association for Cancer Immunotherapy (CIMT) meeting
Apr 16, 2014
'Tromsø company attracts attention at cancer congress' - article in iTromsø
Apr 10, 2014
Lytix Biopharma starts a new company within treatment of dementia, Pharmasum Therapeutics
Feb 28, 2014
Extraordinary general assembly and shareholder meetings in Lytix Biopharma in March
Jan 29, 2014
Lytix Biopharma has been granted BIA funding for the cancer project (LTX-315)
Nov 22, 2013
Øystein Rekdal from Lytix Biopharma presents at 'Gazelle conference' in Tromsø Monday
Nov 19, 2013
Lytix Biopharma’s antimicrobial drug candidate LTX-109 is one of ‘Top Projects To Watch’
Aug 20, 2013
Lytix Biopharma attended the 53rd ICAAC annual meeting, 10-13 September in Denver, Colorado
May 30, 2013
Lytix Biopharma attended ASCO (American Society of Clinical Oncology) annual meeting 2013
Apr 8, 2013
Lytix Biopharma attended the American Association for Cancer Research (AACR) annual meeting
Apr 3, 2013
Lytix Biopharma's infection drug candidate has the potential to treat and prevent skin infections
Feb 22, 2013
Lytix Biopharma enrolls first patient in LTX-109 Phase II PoC infection study
Feb 22, 2013
220213 Lytix Biopharma enrolls first patient in LTX-109 Phase II PoC infection study.htm
Nov 2, 2012
LTX-109 featured in newspaper article on antibiotic resistance in A-magasinet
Oct 30, 2012
301012 Lytix Biopharma and ABG Sundal COllier signs collaboration agreement
Jul 5, 2012
Future by Semcon presenting Lytix Biopharma and Lytixar in the article "Antibiotics of the future".
May 26, 2011
Successful Proof of Concept for topical antimicrobial drug Lytixar (LTX-109)
Dec 23, 2010
Lytix Biopharma closes successful shares emission | Lytix Biopharma gjennomfører vellykket emisjon
Dec 6, 2010
Lytix Biopharma and KAELGemVax announce first patient treated in clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy
Sep 1, 2010
Lytix Biopharma AS announces approval by Hungarian authorities and ethics committee to start Phase IIa clinical trial with Lytixar (LTX-109) in Gram positive skin infections
Jun 9, 2010
Lytix Biopharma and KAELGemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy
May 20, 2010
Lytix Biopharma AS announces regulatory approval by Swedish authorities to commence Phase I/IIa clinical trial with Lytixar (LTX-109) in MRSA
May 20, 2010
Lytix Biopharma AS update on phase I progress with Oncopore for solid tumours
May 4, 2010
Lytix Biopharma AS to hold General Assembly of Shareholders on 4th June 2010
Dec 14, 2009
Lytix Biopharma AS announces regulatory approval by Norwegian and Swedish authorities to commence Phase I clinical trial of OncoporeTM (LTX-315) in cancer
Sep 23, 2009
Lytix Biopharma presented new data on antimicrobial drug LytixarTM (LTX-109) at ICAAC
Jun 18, 2009
Lytix Biopharma and KAELGemVax announce joint clinical trial to combine LTX-315 and GV1001 cancer immunotherapy